Marshall Fordyce, MD

Marshall Fordyce, MD is Co-founder, President and Chief Executive Officer of Trucode. He brings more than 10 years of experience leading teams in drug discovery, development, clinical translation, and commercialization. Prior to founding Trucode, he was an entrepreneur in residence at Kleiner Perkins. Previously, Dr. Fordyce served as Senior Director of Clinical Research at Gilead Sciences, where he contributed to seven new drug approvals and served as Project Lead for Gilead’s highly successful TAF/GENVOYA development program.  With subspecialty training in infectious disease from Columbia P&S, Dr. Fordyce was previously Chief Resident at NYU Bellevue and spent two years as translational research fellow at Rockefeller University. Dr. Fordyce has been an advisor to Google X and to several private biotech companies. He currently serves on the Board of Directors of the Albert and Mary Lasker Foundation. He received his BA from Harvard University and his MD from Harvard Medical School.

Founder, President and Chief Executive Officer

Allen Ebens, PhD

Allen Ebens, PhD is Chief Scientific Officer of Trucode. Dr. Ebens brings over 20 years of drug development experience to Trucode, beginning in drug discovery at Exelixis before moving to Genentech where over 11 years he worked from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, antibody-drug conjugates, and bispecific antibodies. Dr. Ebens was recruited from Genentech to establish the oncology research lab at Juno Therapeutics and later served as Senior Director, Immune Oncology at NGM Biopharmaceuticals. Over a significant career, Dr. Ebens’ contributions include advancement of five discovery projects to clinical development. He is the author of 30 peer-reviewed scientific publications and is an inventor on eight issued patents and over 40 pending patent applications. He earned his PhD at UCLA and completed his post-doctoral training at UCSF.

Chief Scientific Officer 

Lauren Frenz

Lauren Frenz is SVP, Corporate Strategy & Finance at Trucode. Most recently, Ms. Frenz held positions of increasing responsibility at Gilead Sciences, where she led US healthcare provider marketing for GENVOYA, which quickly became the #1 prescribed HIV regimen. She also led launch planning, brand strategy, messaging, and tactic development for ODEFSEY and managed COMPLERA. Prior to her roles in marketing, she served in the Gilead Commercial Planning group and was responsible for development of market insights, long-range forecasting, product positioning, payer value strategies, and global branding in various therapeutic areas. Ms. Frenz previously worked at SVB Leerink in their Strategic Advisory practice, devising business development, commercial, and portfolio management strategies for biopharma companies. She received her AB from Princeton University and MBA from Harvard Business School, and recently served on the Board of the Harvard Business School Healthcare Alumni Association.

SVP, Corporate Strategy & Finance

Jim Coull, PhD

Jim Coull, PhD provides Chemistry Leadership at Trucode. Dr. Coull is a pioneer in peptide nucleic acid (PNA) chemistry, and previously served as CEO for PNA Innovations, Inc., which was acquired by Trucode in 2017. He has extensive background in research and development, intellectual property creation and strategy, as well as building successful life science and diagnostic companies. He has served as CTO of AdvanDx, which created the first FDA-cleared molecular tests for rapid diagnosis of bacterial and fungal bloodstream infections and served as VP of Commercial Operations and subsequently CTO of Ensemble Discovery Corporation. Previously, Dr. Coull co-founded and led R&D at Boston Probes, a company that developed novel PNA-based assays for detecting and quantifying DNA and RNA, which was acquired by Applied Biosystems. Dr. Coull has also held senior leadership positions at Millipore Corporation and PerSeptive Biosystems. He is listed as an inventor on more than 40 issued US patents, has published over 40 peer-reviewed articles, and presented at numerous international scientific meetings and conferences. Dr. Coull received his BS from Colby College and PhD from Purdue University.

PNA Chemistry

Susan K. Whoriskey, PhD

Susan Whoriskey, PhD advises on Technology Strategy and Business Development at Trucode. Previously, she served on the founding Executive Teams of Cubist Pharmaceuticals (CBST), Momenta Pharmaceuticals (MNTA), and Moderna Therapeutics (MRNA). As a member of the Executive Teams, Dr. Whoriskey played key roles in building teams, managing translation of academic inventions into therapeutic modalities, completing venture capital financings, overseeing numerous patent filings, negotiating corporate partnerships, completing IPOs and follow-on financings and achieving four FDA drug approvals to date. She has been a consultant to the venture capital firm Polaris Venture Partners and an Entrepreneur in Residence at MIT. Dr. Whoriskey earned her BS from University of Massachusetts-Amherst and PhD from UCLA and was a Research Fellow in Molecular Genetics at Harvard Medical School with 2009 Nobel Prize winner Dr. Jack Szostak. She is a recipient of an Honorary Doctorate in Biotechnology and Entrepreneurism from the University of Ulster.

Technology Strategy & Business Development

  • Twitter
  • LinkedIn - Black Circle

© 2019 Trucode Gene Repair, Inc.